LadRx

LadRx ROCE

The Return on Capital Employed (ROCE) of LadRx (LADX) as of Oct 17, 2026 is 255.27 %. In the previous year, Return on Capital Employed (ROCE) was -3,561.42 % — a change of -107.17% (higher).

ROCE

255.27 %

YoY

-107.17%

Last updated:

In 2024, LadRx's return on capital employed (ROCE) was 255.27 %, a -107.17% increase from the -3,561.42 % ROCE in the previous year.

The LadRx ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-40.51 USD
Jan 1, 2019
-51.71 USD
Jan 1, 2020
-76.99 USD
Jan 1, 2021
-125.20 USD
Jan 1, 2022
-17,729.41 USD
Jan 1, 2023
-3,561.42 USD
Jan 1, 2024
255.27 USD
The LadRx ROCE history
YEARROCEYoY
255.27 %-107.17%
-3,561.42 %-79.91%
-17,729.41 %+14,061.10%
-125.20 %+62.62%
-76.99 %+48.90%
-51.71 %+27.64%
-40.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LadRx Stock analysis

What does LadRx do? LadRx Corp, with ticker LADX and ISIN US2328287071, is a biotechnology company headquartered in Los Angeles, United States. The company has 2 employees and went public on November 10, 1986. Its website is http://www.cytrx.com/. LadRx Corp operates within the Health Care sector, specifically in the Biotechnology industry. The company's activities include the discovery, research, and clinical development of anti-cancer drug candidates. It focuses on aldoxorubicin, a modified version of doxorubicin, for clinical development. The company is involved in Phase III trials for aldoxorubicin as a treatment for soft tissue sarcoma in patients whose tumors have progressed after chemotherapy. Additionally, LadRx Corp is conducting Phase IIb trials for aldoxorubicin in small cell lung cancer, Phase II trials for HIV-related Kaposi's sarcoma, and Phase II trials for late-stage glioblastoma. The company also has Phase Ib trials combining aldoxorubicin with ifosfamide for soft tissue sarcoma and with gemcitabine for metastatic solid tumors. LadRx Corp is developing DK049, an anti-cancer drug conjugate utilizing its LADR technology, in pre-clinical stages. The company's website and public filings provide further details on its operations and clinical trials. LadRx is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling LadRx's Return on Capital Employed (ROCE)

LadRx's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing LadRx's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

LadRx's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in LadRx’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about LadRx stock

Return on Capital Employed (ROCE) of LadRx is 255.27 % in 2024.

Return on Capital Employed (ROCE) of LadRx changed from -3,561.42 % to 255.27 %, representing a -107.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) LadRx since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s LadRx with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — LadRx

All Key Metrics — LadRx